ClinVar Miner

Submissions for variant NM_001077488.4(GNAS):c.139+1G>C

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Illumina Clinical Services Laboratory,Illumina RCV001095787 SCV001251636 pathogenic Pseudohypoparathyroidism type 1B 2020-02-19 criteria provided, single submitter clinical testing The GNAS c.139+1G>C variant occurs in a canonical splice site (donor) and is therefore predicted to disrupt or distort the normal gene product. This variant has been reported in at least three studies in which it was identified in a heterozygous state in three individuals affected with pseudohypoparathyroidism Ia (PHP-Ia), either maternally inherited or in a de novo state on the maternal allele (Alvarez et al. 2010; Richards et al. 2013). The variant has also been reported in a heterozygous state in an individual affected with progressive osseous heteroplasia (POH) in a de novo state on the paternal allele (Lebrun et al. 2010). The c.139+1G>C variant is not found in the Genome Aggregation Database in a region of good sequence coverage, so the variant is presumed to be rare. Based on the collective evidence, the c.139+1G>C variant is classified as pathogenic for disorders of GNAS inactivation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.